Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00947882

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) — DELUTS  

Lower Urinary Tract Symptoms (LUTS) Clinical Trial

Official title:
A Dose-Finding, Multi-Centre, Double-Blind, Randomised, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Clinical Trial Summary

A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00947882
Study type Interventional
Source Ferring Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date August 2009
Completion date June 2011
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987138 - Safety and Effectiveness Study of the Zenflow Spring System N/A
Completed NCT03856242 - Benign Prostatic Hyperplasia and Ischemic Heart DIsease Phase 4
Recruiting NCT02592473 - Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT01639794 - Vesitirim™ in Men Postmarketing Observational Study N/A
Terminated NCT00743184 - Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH) Phase 2
Recruiting NCT05341661 - Butterfly Pivotal Study N/A
Completed NCT01846793 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) Phase 3